{"Clinical Trial ID": "NCT01663727", "Intervention": ["INTERVENTION 1:", "- Paclitaxel+Placebo", "Participants received paclitaxel 90 mg/m^2 IV on days 1, 8 and 15 and placebo corresponding to the infusion of bevacizumab IV on days 1 and 15 of a 28-day cycle to progressive disease, treatment limiting toxicity or death.", "INTERVENTION 2:", "- Paclitaxel+ Bevacizumab", "Participants received paclitaxel 90 mg/m^2 IV on days 1, 8 and 15 and bevacizumab IV 10 mg/kg on days 1 and 15 of a 28-day cycle until progressive disease, treatment limiting toxicity or death."], "Eligibility": ["Incorporation criteria:", "The HER2-negative adenocarcinoma of the breast, confirmed histologically or cytologically, with locally measurable or non-measurable recidivant or metastatic disease. The local recurrent disease must not be susceptible to resection with curative intent.", "ECOG performance status of 0 or 1", "For women of childbearing potential, the use of an acceptable and effective method of non-hormonal contraception", "For patients who have received recent radiation therapy, pre-randomisation recovery from any significant acute toxicity and radiological treatments should be completed more than 3 weeks after randomization.", "- Exclusion criteria:", "\u25ba Disease-specific exclusions:", "HER2-positive status", "\u2022 Prior chemotherapy for a local recidivant or metastatic disease", "Previous hormonal treatment < 2 weeks prior to randomisation", "\u2022 Prior adjuvant or neo-adjuvant chemotherapy is permitted, provided that it has been concluded for at least 12 months prior to randomisation.", "\u25cf Experimental treatment within 28 days of randomization", "General medical exclusions:", "Life expectancy < 12 weeks", "Inadequate function of organs", "A serious medical or psychiatric disease that is uncontrolled", "\u2022 Active infection requiring intravenous antibiotics (IV) during screening", "Pregnancy or lactation", "\u2022 History of other malignancies within 5 years of screening, with the exception of tumours with a negligible risk of metastasis or death"], "Results": ["Performance measures:", "Percentage of participants who have progressed or died in the population intending to treat (ITT)", "The evaluation of tumours was carried out according to the criteria for evaluating the response in version 1.1 of solid tumours (RECIST v1.1) by the investigator. Disease progression was defined as an increase of at least 20 percent (%) in the sum of the diameters of the target lesions compared to the smallest sum of the diameters under study and an absolute increase of at least 5 mm (mm), an unequivocal progression of existing non-target lesions or the presence of new lesions.", "Timeline: Basic data, every 8 weeks until disease progression, death or documented clinical limit (up to 117.7 weeks)", "Results 1:", "Title of the arm/group: Paclitaxel+Placebo", "The participants received paclitaxel 90 mg/m^2 IV on days 1, 8 and 15 and placebo corresponding to the infusion of bevacizumab IV on days 1 and 15 of a 28-day cycle until disease progression, treatment limiting toxicity or death.", "Total number of participants analysed: 242", "Type of measurement: Number", "Unit of measure: percentage of participants 69.4", "Results 2:", "Title of arm/group: Paclitaxel+ Bevacizumab", "The participants received paclitaxel 90 mg/m^2 IV on days 1, 8 and 15 and bevacizumab IV 10 mg/kg on days 1 and 15 of a 28-day cycle until progressive disease, treatment limiting toxicity or death.", "Total number of participants analysed: 239", "Type of measurement: Number", "Unit of measure: percentage of participants 63.6"], "Adverse Events": ["Undesirable Events 1:", "Total: 45/233 (19.31 per cent)", "Anemia * 2/233 (0.86%)", "Febrile neutropenia * 0/233 (0.00 %)", "Leukopenia * 1/233 (0.43%)", "Neutropenia * 1/233 (0.43%)", "Atrial fibrillation * 1/233 (0.43%)", "Left ventricular dysfunction * 0/233 (0.00 %)", "ACUTE CORONARY SYNDROME * 0/233 (0.00 %)", "* 1/233 (0.43%)", "Optimal nervous disorder * 1/233 (0.43%)", "Adverse Events 2:", "Total: 66/238 (27.73 per cent)", "Anemia * 1/238 (0.42%)", "* 4/238 (1.68 per cent)", "Leukopenia * 1/238 (0.42%)", "Neutropenia * 0/238 (0.00 %)", "Atrial fibrillation * 0/238 (0.00 %)", "Left ventricular dysfunction * 1/238 (0.42%)", "ACUTE CORONARY SYNDROME * 1/238 (0.42%)", "* 0/238 (0.00 %)", "Optimal nervous disorder * 0/238 (0.00 %)"]}